Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment

International Urology and Nephrology

Volumn 28, Issue 3, 1996, Pages 349-355

  Kubota, Y ^a   Yanai, H ^a   Sasagawa, I ^a   Suzuki, H ^a   Nakada, T ^a   Sugano, O ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b Yamagata Pref Office   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; FOSFESTROL; IFOSFAMIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PROSTATE CANCER;

EID: 0029788598     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550497     Document Type: Article

References (11)

1. Oesterling, J. E., Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J. Urol., 145, 907 (1991).
2. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E , Freiha, F. S., Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317, 909 (1987).
3. Carter, H. B., Morrell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E J., Chan, D. W , Fozard, J. L., Walsh, P. C.: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res., 52, 3323 (1992).
4. Schmid, H P., McNeal, J. E., Stamey, T. A.: Observations on the doubling time of prostate cancer. Cancer, 71, 2031 (1993).
5. Pollack, A., Zagars, G. K., Kavadi, V. S.: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer, 74, 670 (1994).
6. Young, C. Y., Montgomery, B T., Andrews, P. E., Qui, S. D., Bilhartz, D. L., Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51, 3748 (1991).
7. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F , Tindall, D. J.: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21, 63 (1992).
8. Hanks, G. E., D'Amico, A., Epstein, B. E., Schultheiss, T. E.: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int. J. Radiat. Oncol. Biol. Phys., 27, 125 (1993).
9. Leo, M. E., Bilhartz, D. L., Bergstrahl, E. J., Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J. Urol., 145, 802 (1991).
10. Cadeddu, J. A., Pearson, J. D., Partin, A. W., Epstein, J. I., Carter, H. B.: Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology, 42, 383 (1993).
11. D'Amico, A. V., Hanks, G. E.: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, 72, 2638 (1993).